MedTrace Logo

18F-LY3950321-01 Biodistribution and Safety Study

NCT05775601 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-04-28

No results posted yet for this study

Summary

18F-LY3950321 (also known as 18F-MNI-1256) is a radiolabeled positron emission tomography (PET) tracer targeting granzyme B. The overall goal of this protocol is to evaluate the safety, tolerability, and radiation dosimetry of 18F-LY3950321.

Conditions

  • Diagnostic Agent Adverse Reaction
  • Radiation Exposure

Interventions

DRUG

18F-LY3950321

3 millicuries (±1 mCi)

PROCEDURE

PET Scan

positron emission tomography (PET) scan

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Avid Medical Director · Avid Radiopharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-04-04
Completion
2023-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05775601 on ClinicalTrials.gov